Novartis AG has begun two head-to-head trials looking to show superiority of Cosentyx (secukinumab) over the world's biggest-selling drug – AbbVie Inc.'s Humira (adalimumab) – for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Thanks to its success as a treatment for psoriasis, Cosentyx is already a big earner for the Swiss major, bringing...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)